1. Academic Validation
  2. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members

  • Nature. 2003 Aug 14;424(6950):793-6. doi: 10.1038/nature01803.
Eirini Trompouki 1 Eudoxia Hatzivassiliou Theodore Tsichritzis Hannah Farmer Alan Ashworth George Mosialos
Affiliations

Affiliation

  • 1 Institute of Immunology, Biomedical Sciences Research Center 'Alexander Fleming', 34 Alexander Fleming Street, Vari 16672, Greece.
Abstract

Familial cylindromatosis is an autosomal dominant predisposition to tumours of skin appendages called cylindromas. Familial cylindromatosis is caused by mutations in a gene encoding the CYLD protein of previously unknown function. Here we show that CYLD is a deubiquitinating Enzyme that negatively regulates activation of the transcription factor NF-kappaB by specific tumour-necrosis factor receptors (TNFRs). Loss of the deubiquitinating activity of CYLD correlates with tumorigenesis. CYLD inhibits activation of NF-kappaB by the TNFR family members CD40, XEDAR and EDAR in a manner that depends on the deubiquitinating activity of CYLD. Downregulation of CYLD by RNA-mediated interference augments both basal and CD40-mediated activation of NF-kappaB. The inhibition of NF-kappaB activation by CYLD is mediated, at least in part, by the deubiquitination and inactivation of TNFR-associated factor 2 (TRAF2) and, to a lesser extent, TRAF6. These results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-kappaB that is required for appropriate cellular homeostasis of skin appendages.

Figures